Neximmune

Neximmune FCF Margin

Free Cash Flow Margin of Neximmune (NEXI) as of Oct 18, 2026.

FCF Margin

-

Last updated:

Free Cash Flow Margin of Neximmune is 2026 - . Free Cash Flow Margin of Neximmune was 2025 - . It decreases by % lower compared to the previous year.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Neximmune Stock analysis

What does Neximmune do? Neximmune Inc, trading under ticker NEXI, is a US-based biotechnology company headquartered in Gaithersburg. Founded in 2021, the company went public on February 12, 2021. It employs 50 people and operates in the Health Care sector. Neximmune focuses on developing immunotherapies using its Artificial Immune Modulation (AIM) platform, which employs nanoparticles to direct T cell responses. The company's product candidates include NEXI-001 for acute myeloid leukemia and NEXI-002 for multiple myeloma. Its AIM technology constructs synthetic dendritic cells to generate targeted immune responses. The company is clinical-stage, developing treatments for oncology and autoimmune disorders. Neximmune is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neximmune stock

On Eulerpool you can find the complete historical development of Free Cash Flow Margin Neximmune since 2006 – with annual values, charts, and detailed analysis.

FCF Margin measures the percentage of revenue converted to free cash flow. It indicates how efficiently a company generates cash from its operations.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow Margin's Neximmune with sector peers and the industry average to assess whether it is attractive.

To evaluate Free Cash Flow Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Free Cash Flow Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Neximmune

All Key Metrics — Neximmune